Hospital
Genesis Health System
Genesis Health System was paid $44.32M by Medicaid between Jan 2018 and Dec 2024, across 156 billing codes. Its largest line is 99284, emergency room visit (serious) — 34% of everything it billed.
33Billing provider infoGENESIS HEALTH SYSTEM
DAVENPORT, IA 52803
DAVENPORT, IA 52803
33aNPI1972542264assigned 06/05/2006
33bProvider typeSubstance Use Disorder Rehabilitation Hospital Unit
28Total paid$44.32M
24GClaims819,292
24DCodes billed156
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 143,494 | $7.52M | |
| 2019 | 148,097 | $7.51M | |
| 2020 | 115,920 | $5.74M | |
| 2021 | 135,412 | $7.08M | |
| 2022 | 113,081 | $6.29M | |
| 2023 | 95,647 | $5.60M | |
| 2024incomplete | 67,641 | $4.59M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 34% | 63,781 | 60,919 | $15.03M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 56,467 | 54,531 | $8.35M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 16% | 21,691 | 20,508 | $7.23M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 9.6% | 32,811 | 31,284 | $4.25M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3.0% | 18,485 | 14,735 | $1.34M |
| 71046 | Radiologic examination, chest; 2 views | 2.0% | 17,516 | 16,662 | $900K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.8% | 15,592 | 14,109 | $804K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.5% | 18,635 | 17,304 | $681K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.4% | 15,571 | 3,845 | $617K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.4% | 15,129 | 4,320 | $611K |
| 71045 | Radiologic examination, chest; single view | <1% | 7,215 | 6,762 | $385K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 52,735 | 44,804 | $383K |
144 more codes
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 8,837 | $369K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,373 | $355K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 10,797 | $340K |
| 97597 | <1% | 7,229 | $339K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 3,671 | $304K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,500 | $303K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 551 | $284K |
| 59025 | Fetal non-stress test | <1% | 1,976 | $267K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 2,883 | $264K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,487 | $134K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 717 | $126K |
| 64615 | <1% | 459 | $78K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,605 | $54K |
| 62323 | <1% | 103 | $40K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 99 | $39K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 84 | $35K |
| 95912 | <1% | 118 | $34K | |
| 96367 | <1% | 258 | $32K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 223 | $28K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 183 | $26K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,074 | $23K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 28,884 | $18K |
| 80053 | Comprehensive metabolic panel | <1% | 66,326 | $18K |
| 36415 | Collection of venous blood by venipuncture | <1% | 11,389 | $17K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 543 | $17K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 41 | $17K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 70,034 | $14K |
| 20611 | <1% | 61 | $12K | |
| 87536 | <1% | 182 | $10K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 773 | $10K |
| G0379 | Direct admission of patient for hospital observation care | <1% | 462 | $10K |
| 64493 | <1% | 16 | $10K | |
| 97803 | <1% | 512 | $9K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 818 | $8K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,662 | $6K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 277 | $6K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 277 | $5K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 16,001 | $5K |
| 83605 | <1% | 21,600 | $4K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,671 | $4K |
| 86360 | <1% | 119 | $4K | |
| 83690 | <1% | 24,649 | $3K | |
| 87400 | <1% | 12,571 | $3K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 13 | $3K |
| G0378 | Hospital observation service, per hour | <1% | 833 | $3K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 25 | $3K |
| 81003 | <1% | 12,890 | $2K | |
| 86738 | <1% | 2,150 | $2K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 20 | $2K |
| 97161 | <1% | 32 | $2K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 41 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 12,327 | $2K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 7,888 | $2K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 56 | $2K |
| 97802 | <1% | 137 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,824 | $2K |
| 97162 | <1% | 23 | $2K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 9,507 | $1K |
| 83735 | <1% | 19,981 | $1K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 18 | $1K |
| 83655 | <1% | 96 | $1K | |
| 87522 | Neg quan hep c or qual rna | <1% | 25 | $1K |
| 81025 | <1% | 10,864 | $999.82 | |
| 80061 | Lipid panel | <1% | 104 | $934.99 |
| 76642 | <1% | 12 | $890.78 | |
| 97165 | <1% | 14 | $802.77 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 5,643 | $671.30 |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 12 | $670.53 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 276 | $669.06 |
| 95886 | <1% | 995 | $618.16 | |
| 81001 | <1% | 25,572 | $571.70 | |
| 84484 | <1% | 18,614 | $505.59 | |
| 86592 | <1% | 161 | $482.17 | |
| 97598 | <1% | 46 | $480.54 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 280 | $447.30 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 447 | $416.33 |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 9,105 | $374.12 |
| 87081 | <1% | 4,300 | $307.97 | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 26 | $291.14 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,666 | $236.41 |
| 86361 | <1% | 13 | $221.85 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 505 | $217.08 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,843 | $214.46 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 136 | $213.59 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 14 | $208.02 |
| 72100 | <1% | 16 | $199.24 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 136 | $176.81 |
| 85610 | <1% | 2,423 | $172.91 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 42 | $170.69 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 45 | $161.08 |
| 87420 | <1% | 871 | $159.23 | |
| 86803 | <1% | 15 | $156.96 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 262 | $152.09 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 438 | $137.13 |
| 85018 | <1% | 59 | $133.68 | |
| 82803 | <1% | 2,077 | $112.80 | |
| 86900 | <1% | 51 | $108.23 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 14 | $99.62 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 301 | $92.17 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 17 | $78.84 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 79 | $77.42 |
| 83880 | <1% | 418 | $74.88 | |
| 82550 | <1% | 882 | $66.87 | |
| 84100 | <1% | 257 | $50.91 | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 632 | $50.20 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 162 | $44.44 |
| 85379 | <1% | 627 | $40.06 | |
| 83615 | <1% | 73 | $37.58 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 285 | $28.47 |
| 86141 | <1% | 327 | $25.34 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 42 | $24.76 |
| 85027 | <1% | 282 | $24.17 | |
| 85730 | <1% | 489 | $23.52 | |
| 82009 | <1% | 846 | $21.89 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 29 | $16.76 |
| 84702 | <1% | 121 | $14.73 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 45 | $11.71 |
| 82948 | <1% | 206 | $10.95 | |
| 87186 | <1% | 56 | $8.47 | |
| 87077 | <1% | 13 | $7.91 | |
| 84703 | <1% | 297 | $7.35 | |
| 87040 | <1% | 994 | $6.64 | |
| A9270 | Non-covered item or service | <1% | 1,421 | $0.24 |
| 64494 | 0% | 15 | $0.00 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 0% | 18 | $0.00 |
| 87070 | 0% | 45 | $0.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 13 | $0.00 |
| 74022 | 0% | 36 | $0.00 | |
| 86901 | 0% | 55 | $0.00 | |
| 86850 | 0% | 28 | $0.00 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 13 | $0.00 |
| 87581 | 0% | 14 | $0.00 | |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 13 | $0.00 |
| 85651 | 0% | 15 | $0.00 | |
| 88304 | 0% | 12 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 14 | $0.00 |
| 96376 | 0% | 23 | $0.00 | |
| 87210 | 0% | 115 | $0.00 | |
| 80076 | 0% | 140 | $0.00 | |
| 73630 | 0% | 15 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 58 | $0.00 |
| 73130 | 0% | 16 | $0.00 | |
| 73610 | 0% | 14 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCROME, CHRISTOPHER (COO)
| Provider | Location | Paid |
|---|---|---|
| Genesis Health System | Davenport, IA | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.